2015

  • IPO – Listed on Oslo Stock Exchange raising NOK 575 million in gross proceeds ($ 72 million*)
    *NOK 1 = $ 8.06 as at 31 March 2015

2014

  • Name change from Nordic Nanovector AS to ASA
  • Subsequent repair issue of NOK 50 million
  • The Board appoints Mr. Luigi Costa as new CEO
  • Successful closing of NOK 250 million pre-IPO private placement
  • Orphan-drug designation in the US and in EU granted 
  • Betalutin™ clinical trial advances to phase 2
  • New Clinical Advisory Board established
  • Betalutin™ patent approved in US and in Europe

2013

  • HealthCap VI L.P ("HealthCap") commits to invest NOK 50 million
  • Successful closing of a Private Placement of NOK 60 million
  • Inspection by Norwegian Medicines Agency successfully completed

2012

  • First patient included in Betalutin® clinical trial
  • Ready-to-use Betalutin® formulation developed
  • Regulatory approval to proceed with phase 1/2 clinical trial in Norway
  • Regulatory approval to proceed with phase 1/2 clinical trial in Sweden

2011

  • The Company moves operations from the Norwegian Radium Hospital to Kjelsåsveien 168 B and first full-time employees are hired
  • First patent application approved In Norway.

2010

  • First patent application filing for Betalutin®

2009

  • Nordic Nanovector AS is established in Oslo, Norway